The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions

Kambayashi, Harutaka; Omori, Teppei; Saito, Satomi; Murasugi, Shun; Kashiwagi, Hirokazu; Ito, Ayumi; Yonezawa, Maria; Nakamura, Shinichi; Tokushige, Katsutoshi

doi:10.2169/internalmedicine.5000-20

Cited by 4 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Previous studies have shown that anti-TNF agents, including infliximab and adalimumab, led to the relief of gastrointestinal symptoms and ulcers in gastrointestinal tract in patients with Behcet's disease. [15][16][17][27][28][29][30][31][32][33][34][35][36] However, these studies were single-arm cohort studies. No randomized clinical trials have been conducted in this field.…”

Section: Discussionmentioning

confidence: 99%

“…Gastrointestinal involvement was considered more dangerous to patients with Behcet's disease, as the prognosis was usually worse 9 . Previous studies have shown that anti‐TNF agents, including infliximab and adalimumab, led to the relief of gastrointestinal symptoms and ulcers in gastrointestinal tract in patients with Behcet's disease 15–17,27–36 . However, these studies were single‐arm cohort studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and safety of anti‐tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta‐analysis

Zhang

Liu

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim: Behcet's disease is a systemic vasculitis that can involve gastrointestinal tract. This is a systematic review and meta-analysis evaluating the efficacy and safety of anti-tumor necrosis factor (TNF) agents in treating patients with intestinal Behcet's disease. Methods: We conducted searches on PubMed, Embase, and Cochrane. Data from eligible studies were used to calculate the pooled estimate of proportions of clinical remission, mucosal healing at Months 3, 6, 12, and 24 as well as the pooled incidence of adverse drug reactions. And subgroup analysis based on the specific type of anti-TNF agents was performed. Results: Of the 828 studies initially identified, 13 were included finally, all of which were single-arm cohort studies. The pooled proportions of clinical remission at Months 3, 6, 12, and 24 were 0.61 (95%CI 0.48-0.78), 0.51 (95%CI 0.40-0.66), 0.57 (95%CI 0.48-0.67), and 0.38 (95%CI 0.16-0.88), respectively. The pooled proportions of mucosal healing at Months 3, 6, 12, and 24 were 0.66 (95%CI 0.50-0.86), 0.82 (95%CI 0.48-0.98), 0.65 (95%CI 0.51-0.81), and 0.69 (95%CI 0.39-1.00), respectively. The pooled estimate of proportion of overall adverse drug reactions for infliximab was 0.22 (95%CI 0.07-0.69). Conclusions: Anti-TNF agents, including infliximab and adalimumab, were an efficient therapy for intestinal Behcet's disease. The safety of anti-TNF agents used in the treatment of intestinal Behcet's disease was acceptable.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of anti‐tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta‐analysis

Zhang

Liu

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Of the 12 included studies, 8 were retrospective studies and 4 were prospective studies. 21 , 22 , 26 – 34 Only one retrospective study made a comparison with the control group, 32 while the remaining 11 studies were single-arm type. The population of patients with ADA treatment reported by Inoue et al 21 was the same as that reported by Tanida et al ., 29 but the latter focused on a longer time.…”

Section: Resultsmentioning

confidence: 99%

Anti-TNF-α agents for refractory intestinal Behçet’s disease: case series and meta-analysis

Zhan

Liu

et al. 2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Behçet’s disease (BD) is a relapsing systemic immune disorder, and intestinal BD is a significant cause of mortality in patients with BD. Conventional therapeutic strategies for intestinal BD showed unsatisfactory outcomes, especially in those patients with refractory subtypes. In recent years, biologic agents have exhibited promising results in this field. While the sample sizes of existing studies were limited, the results were heterogeneous. Objectives: This study aimed to observe the efficacy of different biologics in clinical symptomatic improvement and intestinal mucosal healing. Design: This is a study including the report of case series and meta-analysis. Data sources and methods: This meta-analysis was conducted following the PRISMA guidelines. Free-text words and subject terms, including ‘Behcet’s Syndrome’, ‘Biologics’, ‘Tumor Necrosis Factor Antagonist’, were used to systematically research the relevant studies in the electronic databases (PubMed, Web of Science, Embase, and Cochrane Library). All retrieved articles were from inception to July 2021, and the data from our institution were also included in this meta-analysis. A double arcsine transformation was performed to stabilize the variance of the original ratio. Heterogeneity was evaluated via Q-test and I2 statistics. Random-effects or fixed-effects model was used to calculate the pooled parameters, and the results were presented as forest plots with 95% confidence intervals. Results: Twelve studies were included, but only antitumor necrosis factor alpha (anti-TNF-α) agents were prescribed as biologicals for refractory intestinal BD. The symptom improvement rates at our institution ranged from 57.1 to 81.8%, and the mucosal healing rates were from 20 to 60% in different therapeutic periods. A total of 514 patients were enrolled in the meta-analysis, and the synthesized ratios showed that 59.8% ( n = 377) and 73.7% ( n = 317) of patients who received maintenance therapy with anti-TNF-α agents could achieve clinical symptomatic improvement during short-term (10–14 weeks) and long-term (48–54 weeks) periods, respectively. Furthermore, 77.8% ( n = 229) of patients with intestinal BD maintained therapeutic efficacy for a longer time (100 weeks). In addition, 60.9% ( n = 120) of the patients achieved sustained intestinal mucosal healing during a long-term follow-up (24–52 weeks). Conclusion: Anti-TNF-α treatment is effective in treating refractory intestinal BD but more studies are required to evaluate the effects of new biologics for intestinal BD in the near future. Registration: This study has been registered on PROSPERO, the ID is CRD42022329211. Plain language summary Anti-TNF-α agents are effective and safe in patients with intestinal Behçet’s disease Behçet’s disease (BD) is a disease affecting several organs including the gastrointestinal tract. Nowadays, the efficacy of existing therapy strategies is still unsatisfactory and some patients are suffering from repeated attacks of the disease. We noticed that a new kind of medicine, called antitumor necrosis factor alpha (anti-TNF-α) agents, was applied to these patients recently. The therapeutic efficacy is not convincing enough to evaluate since the number of patients receiving this new medicine was small in every individual study. Regarding this, we conducted a research to learn about the efficacy of this medicine at our own institution. Besides, we composed the results of other studies in an appropriate way. Then, we drew a conclusion on the exact efficacy of anti-TNF-α agents after the data analysis. We unveiled that the anti-TNF-α agents appeared both effective and safe in the management of intestinal BD patients when the classical therapy failed. More than half of the patients could achieve discomfort remission when they got the therapy of the new medicine at our institution. We also found that intestinal ulcers in most patients improved after they received the treatment. All in all, it offered another foothold for getting relief in these patients who were caught in this mire.

show abstract

“…Many reports confirmed the efficacy of anti-TNF-α antibody (infliximab/adalimumab) in the treatment of EB, where the remission rate can reach 80-89% [22][23][24]. There are also reports on the long-term efficacy of anti-TNF-α antibodies in treating EB [22]. Anti-TNF-α antibodies were also effective in preventing postoperative recurrence with a recurrence-free state for 2-3 years.…”

Section: Anti-tnf-alpha Agentsmentioning

confidence: 94%

Section: Anti-tnf-alpha Agentsmentioning

confidence: 95%

Entero-Behcet: A Challenging Aspect of Behçet’s Disease

Allaoui¹,

Belabbess²,

Jabbouri³

et al. 2023

Rare Diseases - Recent Advances

View full text Add to dashboard Cite

Behcet disease is a proteiform vasculitis, and it can have multiple presentations. One of these presentations is digestive involvement commonly known as entero-Behcet. It is a challenging presentation of Behcet disease, because of its similarity with other inflammatory digestive diseases, especially Crohn disease, which makes its diagnosis difficult and uncertain in many cases. It is also challenging to treat, and its treatment can go from corticosteroids and immunosuppressive therapy to biologics. The absence of a standardized protocol to treat patients can be confusing for practitioners treating entero-Behcet. This incites doctors treating entero-Behcet to have multidisciplinary meetings to discuss patients’ cases. This review will give an insight into pathophysiology, diagnosis, and management of entero-Behcet to help practitioners taking care of this challenging aspect of entero-Behcet.

show abstract

The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions

Cited by 4 publications

References 22 publications

The efficacy and safety of anti‐tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta‐analysis

The efficacy and safety of anti‐tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta‐analysis

Anti-TNF-α agents for refractory intestinal Behçet’s disease: case series and meta-analysis

Entero-Behcet: A Challenging Aspect of Behçet’s Disease

Contact Info

Product

Resources

About